HCA Healthcare Locks in $2.98 Billion of Debt at Near‑Par Prices, Aims to Retire 2026 Notes

---

HCA Healthcare’s latest financing round reads like a balance‑sheet reshuffle more than a growth‑capital raise. The Nashville‑based hospital operator sold three series of senior notes – $1 billion at 4.700% due 2031, $750 million at 5.000% due 2033 and $1.25 billion at 5.300% due 2036 – at offering prices of 99.856%, 99.780% and 99.674% of par, respectively. Those fractions translate into a gross cash inflow of $2,992,835,000. After the underwriting discounts – 0.350% on the 2031 series, 0.400% on the 2033 series and 0.450% on the 2036 series, totalling $12,125,000 – HCA will walk away with $2,980,710,000.

The pricing, just a hair below 100% of face value, signals a market that is comfortable with HCA’s credit profile but not eager to overpay. In the absence of a disclosed overallotment (greenshoe) option, the underwriters are betting that demand will be satisfied by the initial allocation. The syndicate – led by Goldman Sachs, Morgan Stanley, J.P. Morgan, Citigroup and Bank of America Securities, with Barclays, UBS, Wells Fargo, RBC Capital, Mizuho, BNP Paribas and Truist joining the line‑up – reflects a broad‑based confidence among Wall Street’s debt specialists.

Use of proceeds is crystal‑clear. HCA will deploy $2.5 billion of the net cash to redeem all outstanding senior notes maturing in 2026 – $1.5 billion of 5.250% notes and $1.0 billion of 5.375% notes. The remaining roughly $0.475 billion is earmarked for general corporate purposes, which may include repaying borrowings under its commercial‑paper program, bolstering working capital, or other routine needs.

The filing’s risk‑factor section flags the usual debt‑related concerns. The notes are senior unsecured, ranking behind any future secured borrowing and behind the subsidiaries’ existing and future liabilities – a structural subordination that could erode recovery in a default scenario. The parent guarantee, while senior unsecured, does not extend to all subsidiaries, limiting its protective reach. Fixed‑rate coupons of 4.7%‑5.3% expose investors to interest‑rate risk if market yields climb higher. Finally, the allocation of proceeds to retire existing debt, while fiscally prudent, reduces the cash buffer for operational flexibility.

Market backdrop adds nuance. HCA’s stock slipped 8.7% after a first‑quarter earnings release that missed adjusted EBITDA expectations, and Bernstein trimmed its price target to $503 from $541 on April 28. The broader high‑yield market has been jittery as the Federal Reserve’s policy stance keeps rates elevated, making investors more price‑sensitive on new issue spreads. By pricing the notes within a narrow discount to par, HCA avoids the premium that would be required in a hotter market, but still secures the liquidity needed to extinguish a sizable chunk of maturing debt.

In short, the offering is a disciplined refinancing play. It cleans the balance sheet of near‑term obligations, leaves a modest cash cushion for day‑to‑day needs, and does so without the fanfare of a large discount or a massive greenshoe. For a company navigating earnings volatility and a cautious credit market, the deal underscores a preference for financial stability over aggressive expansion.

---